C hronic heart failure (CHF) is a clinical syndrome characterized by recurrent episodes of decompensation that require constant therapeutic interventions (1) . After occurrence of initial cardiac alterations in heart failure (HF), the failing heart also induces abnormalities in peripheral organs, including the lungs, liver, kidneys, gastrointestinal tract, skeletal muscles, and endocrine system (2) . Together, these abnormalities cause the overall energy balance to shift toward a catabolic state, leading to exercise intolerance and weight loss, both of which strongly determine poor outcome (3, 4) . In this context, circulating biomarkers could be an effective clinical tool, as these cellular signals naturally precede the patient's functional decline and may therefore provide early tissue-specific information on CHF. Similarly, their temporal patterns could help in monitoring disease progression even in the presymptomatic phase, potentially enabling physicians to timely modify therapy to prevent impending decompensation.
Although it has long been known that multiple hormonal and metabolic alterations occur in CHF (5), the biomarkers that reflect these alterations have only recently received increasing attention with the upcoming use of modern -omics technologies that allow us to discover new highly sensitive proteins (6) . To date, ongoing controversy exists concerning the role of these cardiometabolic biomarkers in CHF. Studies have suggested that IGF binding proteins (IGFBPs) 1, 2, and 7 are increased in CHF and are associated with adverse outcomes after myocardial infraction (7) (8) (9) . IGFBPs regulate IGF activity, which is crucial for indirect effects of GH (10) . Of note is that IGFBPs also exhibit IGFindependent effects on the cardiovascular system (11) . In this way, the IGF-IGFBP system has an important role in the regulation of cardiac remodeling, myocardial contractility, and vascular system function (10) . Similarly, the adipose tissue acts as an endocrine organ by secreting adipokines that are involved in a plethora of metabolic functions, including glucose and lipid metabolism, inflammation, atherosclerosis, and cardiac remodeling (12) . Among secreted adipokines, fatty acid binding protein 4 (FABP-4), resistin, and chemerin have recently been linked to CHF (13) (14) (15) . Nevertheless, the scientific evidence on these biomarkers in CHF is limited, and their potential utility remains undetermined.
Therefore, we investigated the associations of the temporal patterns of cardiometabolic biomarker levels and biomarker slopes (i.e., rates of biomarker change per year) with adverse clinical events in patients with CHF who had undergone 3-monthly repeated blood sampling during their outpatient follow-up.
Methods

CHF cohort
The Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis is a prospective cohort study of stable patients with CHF, conducted in Erasmus MC, Rotterdam, and Noordwest Ziekenhuisgroep, Alkmaar, Netherlands (16) . Patients were included if aged $18 years, capable of understanding and signing informed consent, and if CHF had been diagnosed $3 months ago according to European Society of Cardiology guidelines (1, 17, 18) . Patients were ambulatory and stable (i.e., they had not been hospitalized for HF in the past 3 months). The study was approved by the medical ethics committees, conducted in accordance with the Declaration of Helsinki, and registered in ClinicalTrials.gov (NCT01851538). Written informed consent was obtained from all patients. This investigation comprised 263 patients with CHF enrolled during the first inclusion round period (October 2011 until June 2013).
Baseline assessment
All patients were evaluated by research physicians, who collected information on HF-related symptoms and New York Heart Association (NYHA) class and performed a physical examination. Information on HF etiology, left ventricular ejection fraction, cardiovascular risk factors, medical history, and treatment was retrieved primarily from hospital records and was checked in case of ambiguities. History of cardiovascular and other comorbidities was defined as their clinical diagnosis, as recorded in the medical file.
Follow-up and study end points
During the study, all patients were routinely followed at the outpatient clinic by treating physicians who were blinded for biomarker sampling. In addition, study follow-up visits were predefined and scheduled every 3 months (61 month). This 3-month interval was chosen to ensure that blood sampling occurred as often as possible during a relatively long follow-up period (.2 years) while keeping the study burden acceptable for this CHF population. At each study follow-up visit, a short medical evaluation was performed and samples were collected. During follow-up, all medication changes and occurrence of hospitalizations for HF, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, arrhythmias, and cerebrovascular accident; cardiac transplantation; and left ventricular assist device (LVAD) implantation and mortality were recorded in the electronic case report forms, and associated hospital records and discharge letters were collected. Subsequently, a clinical event committee, blinded to the biomarker results, reviewed hospital records and discharge letters and adjudicated the study end points.
The composite end point comprised cardiac death, cardiac transplantation, LVAD implantation, and hospitalization for the management of acute or worsened HF, whichever occurred first. Cardiac death was defined as death from myocardial infarction or other ischemic heart disease (International Classification of Diseases, 10th Revision: I20 to I25); death from other heart disease, including HF (I30 to I45 and I47 to I52); sudden cardiac death (I46); sudden death undefined (R96); or unwitnessed or ill-described death (R98, R99). Hospitalization for acute or worsened HF was defined as a hospitalization for an exacerbation of HF symptoms, in combination with two of the following: brain natriuretic peptide or N-terminal pro-hormone brain natriuretic peptide (NT-proBNP) more than three times the upper limit of normal; signs of worsening HF, such as pulmonary rales, raised jugular venous pressure, or peripheral edema; increased dose or intravenous administration of diuretics; or administration of positive inotropic agents (1).
Study measurements and laboratory analysis
Blood samples were collected at baseline and at each study follow-up visit, and they were processed and stored at 280°C within 2 hours after collection. Treating physicians were unaware of biomarker results as biomarkers were measured batchwise after completion of follow-up. Thus, the biomarker measurements did not lead to drug adjustments. All patients received usual care. All laboratory personnel were blinded for clinical data and patient outcomes.
For efficiency, for the current investigation, we selected all baseline samples, the two samples closest in time to the primary composite end point, and the last sample available for patients in whom the primary end point did not occur during follow-up.
Glomerular filtration rate was determined by the Chronic Kidney Disease-Epidemiology Collaboration equation validated in patients with HF (19) .
The Olink multiplex proximity extension assay platform for new biomarkers
The Cardiovascular Panel III (Olink Proteomics AB, Uppsala, Sweden) was used for analysis of high-abundance proteins. The proteins present in this Olink panel were selected because they have a proven pathophysiological role in cardiovascular disease or are promising in this respect but yet unexplored. This assay is based on proximity extension assay technology (6) . In brief, the assay uses two oligonucleotide-labeled antibodies to bind to their respective target proteins in the sample. When the two antibodies are in close proximity, a new PCR target sequence is formed by a proximity-dependent DNA polymerization event. The resulting sequence is subsequently detected and quantified using standard real-time PCR. Each sample includes two incubations, one extension, and one detection control to determine the lower limit of detection and normalize the measurements. The biomarkers are presented in normalized protein expression units on a log 2 scale. In a validation study, the mean intra-assay and interassay coefficients of variation were 8% and 12%, respectively (6) . For the current investigation, six emerging cardiometabolic biomarkers (IGFBP-1, IGFBP-2, IGFBP-7, FABP-4, resistin, and chemerin) were examined.
Statistical analysis
For the analysis, we used the z score (i.e., the standardized form) of the log 2 -transformed biomarkers to allow for direct comparisons of different biomarkers. For the network analysis, we used only the biomarkers that showed significant correlations based on Pearson's correlation coefficients (P , 0.05). We assessed the clustering coefficient as a measure of the degree to which biomarkers tend to cluster together, where higher coefficients suggest a certain centrality of a biomarker within the network (20) .
To study the effect of baseline characteristics on repeatedly measured biomarkers, linear mixed-effects (LME) models were performed using biomarkers as the dependent variables and baseline characteristics as the independent variables (fixed part). The sampling time was entered into the fixed and random parts of the models.
To estimate the associations between patient-specific biomarker levels and survival, we applied a joint modeling analysis that combines LME models for repeated measurements and Cox survival analysis for time-to-event data (21) . For both the fixed-and random-effects parts of the LME models, linear terms were used for sampling times, and both intercepts and slopes were included in the random-effects design matrix. This allowed the markers' trajectories to differ at baseline and over time. We also estimated the time-dependent slope (i.e., rate of change) of each biomarker from these joint models, indicating whether and by how much the levels are increasing or decreasing and how they relate to patient prognosis. The slope mathematically corresponds to the first derivative of a marker's trajectory and is presented as an annual change in z scores (i.e., D z scores per year).
Besides sampling time, all markers were adjusted as follows: (1) clinical model: Cox and LME models were adjusted for age, sex, diabetes, atrial fibrillation (AF), baseline NYHA class, diuretics, systolic blood pressure, and estimated glomerular filtration rate (eGFR); (2) clinical and time-varying HF medication model: after adjusting for clinical characteristics, biomarker values were extracted from the joint models and entered simultaneously with equivalent doses of carvedilol, enalapril, furosemide, and spironolactone (repeatedly assessed during follow-up) into a time-dependent Cox analysis to examine the incremental value of the new biomarkers over clinical characteristics and medication during follow-up; and (3) cardiac biomarker model: Cox and LME models were adjusted for biomarkers of myocardial stretch and damage [NT-proBNP and cardiac troponin T (c-TnT)]. Data on all variables were complete, except for systolic blood pressure, which was missing in ,5% of patients and for which imputations were applied using the patients' clinical and outcome data. Results are given as hazard ratios (HRs) and 95% CIs per 1-SD increase of the marker's level and per 0.1-SD increase of the slope at any time point during follow-up.
To correct for multiple testing, we performed matrix spectral decomposition, which has previously been demonstrated to be more effective than Bonferroni correction (22) . Consequently, the corrected significance level was set at P , 0.0127 (0.05/4).
All analyses were performed with R Statistical Software using packages nlme and JMbayes (21) . The network analysis was performed using an open source software for exploring and manipulating networks Gephi (the Gephi Consortium, Paris, France) and the matSpD (23) application. Table 1 displays the patients' baseline characteristics. Specifically, the patients who reached the composite end point were older; more frequently had diabetes, AF, lower systolic blood pressure, higher NYHA class, and higher levels of NT-proBNP and c-TnT; and were more frequently on loop diuretics.
Results
Baseline characteristics
Follow-up and study end points
During a median of 2.2 (interquartile range, 1.4 to 2.5) years of follow-up, we collected a total of 1984 blood samples at fixed 3-month intervals [per patient: 9 (interquartile range, 5 to 10) samples], and measured biomarkers in all samples collected at baseline, the two samples closest in time to the composite end point, and the last sample available for event-free patients (567 samples in total). During the follow-up, 70 (27%) patients experienced the composite end point. Specifically, 56 patients were rehospitalized for acute or worsened HF, three patients underwent heart transplantation, two patients underwent LVAD placement, and nine patients died of cardiovascular causes. Figure 1 displays baseline intermarker correlations and crude associations of their serially measured levels with the composite end point (for HRs, see Table 2 ). Of note is that all biomarkers correlated with each other and no clustering was present. The strongest correlations were present within the IGFBP biomarker family and between these biomarkers and NT-proBNP. Similarly, adipokines correlated strongly with each other. (8) 6 (9) 15 (8) Values are presented as number (%) or mean 6 SD unless otherwise indicated.
Network analysis
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF-pEF, heart failure with preserved ejection fraction; HF-rEF, heart failure with reduced ejection fraction; Hs-TnT, high-sensitivity troponin T; IQR, interquartile range; KDOQI, Kidney Disease Outcomes Quality Initiative; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure. Patients' clinical characteristics and cardiometabolic biomarkers during follow-up Table 3 shows the associations between the patients' baseline characteristics and the biomarkers' temporal trends; the reported associations were independent of each other.
IGFBPs
Higher serially measured IGFBP-1 levels during follow-up were associated with increased baseline NTproBNP and c-TnT, as well as lower baseline body mass index (BMI) values [per doubling of NT-proBNP: adjusted b (95% CI), 0.15 SD (0.09 to 0.22), P , 0.001; c-TnT: 0.13 SD (0.02 to 0.24), P = 0.018; BMI: 20.95 SD (21.38 to 20.53), P , 0.001]. Likewise, patients with increased baseline cardiac markers and lower BMI had higher IGFBP-2 levels during follow-up (for regression coefficients, see Table 3 ). The IGFBP-2 levels were also positively associated with older age, higher baseline NYHA class, and impaired baseline eGFR. Similarly, higher IGFBP-7 levels were found in patients with increased baseline cardiac markers and decreased eGFR and in those who were on higher loop diuretic doses. Patients with AF also had markedly increased IGFBP-7 levels.
Adipokines
Higher serially measured FABP-4 levels were associated with increased baseline cardiac biomarkers, higher BMI, female sex, and impaired eGFR. Moreover, patients who were on higher baseline b-blockers and loop diuretic Figure 1 . Network analysis of cardiometabolic biomarkers depicting intermarker correlations and associations with the composite end point. Node color represents the crude association with the composite end point and ranges from white (the weakest) to black (the strongest). Node size represents the clustering coefficient (a measure of the degree to which biomarkers tend to cluster together, suggesting a certain centrality within the biomarker network). The thickness of the line between the biomarkers represents the correlation coefficient (presented only if P , 0.05); a thicker line represents stronger coefficients. HRs and 95% CIs are given per 1-SD increase of the level and per 0.1-SD increase of the annual slope of a biomarker at any point in time during follow-up.
Crude model: Cox model unadjusted, LME model adjusted for sampling time. Clinical model: Cox and LME models adjusted for age, sex, BMI, diabetes, AF, baseline NYHA class, diuretics, systolic blood pressure, eGFR, and sampling time (LME). Clinical and time-varying medication model: time-dependent Cox model using a biomarker's fitted values from the clinical model adjusted for total daily doses of equivalents of carvedilol, enalapril, furosemide, and spironolactone during follow-up. Cardiac biomarkers model: Cox and LME models adjusted for baseline NT-proBNP and c-TnT, as well as sampling time (LME). a P value below the corrected significance level for multiple testing (P , 0.0127).
b Not performed because marker's levels were not significant in clinical model.
c Annual slopes were additionally adjusted for the levels of serially measured biomarker during follow-up.
doses had higher FABP-4 levels during follow-up. Higher serially measured resistin levels were found in patients with AF and in those with increased NT-proBNP and decreased eGFR levels. During follow-up, higher serially measured chemerin levels were associated with female sex, higher baseline BMI, decreased eGFR, and higher loop diuretic doses.
Temporal evolutions of IGFBPs and adipokines in relation to study end points Average temporal trajectories of cardiometabolic biomarkers in patients who experienced an incident end point and those who did not are displayed in Fig. 2 . In patients with an incident end point, all biomarkers showed increasing patterns to various degrees, with the steepest rise seen in IGFBP-1, IGFBP -2, IGFBP-7, and FABP-4 levels prior to the occurrence of the end point. These biomarkers remained significant predictors even after controlling for baseline NT-proBNP and c-TnT levels. Notably, their higher slopes were strong predictors independently of their absolute levels, baseline clinical characteristics and cardiac biomarkers, and HF medication during follow-up. Serially measured resistin predicted the end point independently of the patients' clinical characteristics and pharmacological treatment but lost significance after controlling for cardiac markers. The chemerin did not show clear prognostic value after multivariable adjustments (Table 2) .
Discussion
To our knowledge, this study is the first to demonstrate that temporal patterns of IGFBP-1, IGFBP-2, IGFBP-7, and FABP-4 strongly predict adverse clinical outcomes in CHF. Independently of the absolute biomarker levels, their higher slopes (i.e., higher rates of change) were also strong clinical predictors. All aforementioned associations were robust to the multivariable adjustment for baseline clinical characteristics and cardiac natriuretic The effects of the patients' baseline characteristics are given as adjusted b (95% CI) per 1-SD differences of biomarkers as measured on the log 2 scale. This method allows a direct comparison of the effects on different biomarkers. All bs are adjusted for patients' age, sex, BMI, DM, AF, baseline NYHA class, SBP, eGFR, NT-proBNP levels, c-TnT levels, and equivalent doses of carvedilol, enalapril, furosemide, and spironolactone. Only the associations with significance level of P , 0.05 are presented.
Abbreviations: DM, diabetes mellitus; NS, not significant; SBP, systolic blood pressure.
doi: 10.1210/jc.2018-01241 https://academic.oup.com/jcempeptide and troponin levels, as well as CHF pharmacological treatment during follow-up.
IGFBPs in CHF
In CHF, an impaired anabolic drive with increased GH levels but peripheral GH resistance, as well as elevated IGFBPs, has been reported (8, 24, 25) . In this regard, studies have suggested that elevated IGFBPs, especially high-affinity IGF binders such as IGFBP-1 and IGFBP-2, indirectly control anabolic activity via their inhibitory function on the GH-IGF-1 axis (11). The IGFBPs also directly control cell growth and survival, which may also contribute to adverse CHF outcomes (11). Our study confirms that patients who experienced adverse clinical events had higher levels of all three IGFBPs than event-free patients, which rose during the follow-up. These elevated IGFBPs might also explain the conflicting results of clinical trials on GH therapy in CHF (26) . A meta-analysis on GH treatment showed that patients with CHF who had a reduced IGF-1 response to GH administration were less likely to benefit from this treatment. Thus, it may be speculated that elevated IGFBPs may be responsible for the "nonresponsiveness" to GH treatment in these patients, but further investigations are needed to confirm this hypothesis.
Besides higher levels, the rise of IGFBP-1, IGFBP-2, and IGFBP-7 over the time course of CHF strongly predicted adverse outcome. In other words, we found elevated risk in patients in whom the levels were increasing (i.e., a higher slope was present) compared with patients with similar IGFBP levels but in whom levels remained constant (for details, see Fig. 3 ). These new insights into IGFBPs' temporal dynamics are important considering the dynamic nature of myocardial remodeling itself, which has a pivotal role in CHF progression. These findings are novel, to our knowledge, and carry clinical implications for the monitoring of patients with CHF.
All three IGFBPs correlated independently with CHF severity, as assessed by cardiac natriuretic peptide and troponin levels. However, IGFBPs differed with respect to their associations with other patient characteristics. Specifically, we found an independent inverse relation between the patients' BMI and IGFBP-1 and IGFBP-2. This has been consistently reported (7, 27) . Thus, it may be speculated that the "obesity paradox," in which higher BMI is associated with better survival in CHF (28) , might be (partially) mediated through the suppressed adverse effects of IGFBP-1 and IGFBP-2. Yet, this association could not be demonstrated between BMI and IGFBP-7. On its part, IGFBP-7 correlated independently with a higher prevalence of AF. In this context, IGFBP-7 has previously been linked to left ventricular diastolic dysfunction (29) and to increased collagen deposition (30) , both of which may contribute to AF. Taking these findings together with the fact that IGFBP-7 belongs to the category of low-affinity IGF binders (31) , it appears that direct effects of IGFBP-7 on the myocardium may predominate in the setting of CHF.
Altogether, on the basis of our findings, we may tentatively hypothesize that preventing alterations in IGFBPs, by means of lowering IGFBP levels, might potentially help protect the myocardium from further damage.
Adipokines in CHF
Adipose tissue has been identified not only as an energy deposit but also as a hormonally active organ that releases numerous bioactive molecules called adipokines (12) . Among them, adipose FABP-4 has been linked to metabolism-related cardiac alterations, including left ventricular hypertrophy and systolic dysfunction (32, 33) . Animal models suggest that adipose FABP-4 causes these cardiac alterations by reducing shortening amplitude and the intracellular systolic Ca 2+ peak in cardiomyocytes (34) . FABP-4 also predicted the onset of HF among an elderly population within the Cardiovascular Health Study (13) . The current study extends these findings by showing that higher FABP-4 levels and a higher rate of change in these levels predict adverse clinical events also in patients with prevalent CHF.
Resistin and chemerin are two other adipokines that are mainly involved in the inflammatory activity underlying cardiovascular diseases (12) . Resistin is largely secreted by mononuclear cells in response to inflammatory stimuli (35) . Animal experiments have demonstrated that in the heart, resistin alters glucose handling, leading to hypertrophy and impaired cardiomyocyte contractility (36) . In murine cardiomyocytes, chemerin was found to induce apoptosis through the activation of several apoptotic mediators (37) . In humans, both resistin and chemerin correlated with left ventricular mass and systolic dysfunction (15, 38) , but their prognostic role in CHF is less firmly established. In this regard, we found increased levels of both biomarkers in patients with CHF who reached adverse events compared with those who did not, but we could not demonstrate their independent prognostic value in CHF.
Cardiometabolic markers as a new link for cardiorenal interaction
We found that repeatedly measured IGFBP-7, FABP-4, resistin, and chemerin are associated with impaired baseline eGFR independently of the patients' characteristics, cardiac markers, and CHF pharmacological treatment. In this context, increased urinary IGFBP-7 has been identified in the settings of acute kidney injury (39) , and FABP-4 has been correlated with renal dysfunction and progression of proteinuria (40) . Similarly, resistin and chemerin have been linked to impaired kidney At the time of assessment, patient C has lower biomarker levels than patients A and B. Corresponding risk in patient C is lower than in patients A and B. By comparing patients A and B, we observe that they have the same biomarker levels. Thus, if we would like to compare these two patients, we have to look at their slopes and relate them to the risk of event. In other words, for two patients with the same biomarker levels, an increase in slope provides us with risk estimates related to the adverse event independently of their levels. These risk estimates are provided in Table 2 under "Slope (per 0.1-SD increase/y)." The dots represent actual biomarker levels.
functioning (14, 41) . Altogether, this raises the question of whether these cardiometabolic biomarkers also represent another link underlying cardiorenal interaction responsible for worse CHF prognosis. However, additional studies, including animal experiments exclusively focusing on this subject, are needed to elucidate this promising concept.
Clinical implications
Our findings, together with previous reports, indicate that the use of cardiometabolic biomarkers for monitoring of CHF progression is a rapidly growing area of interest. The current study explores a potential clinical role of these biomarkers to assist in the care of patients with CHF through better phenotyping of CHF. We found that patients with CHF with higher levels and slopes of IGFBP-1, IGFBP-2, IGFBP-7, and FABP-4 had a more aggressive form of CHF, ultimately leading to adverse outcomes such as rehospitalization or death. This may be important in practice to enable timely adjustment of therapy in patients without clinically overt CHF. These results provide a basis for future studies to further explore this hypothesis. Besides their prognostic role, these biomarkers are bioactive proteins as they activate distinct cell signaling pathways within the IGF-IGFBP system and adipose-related tissue. Therefore, targeting these biomarkers may be a promising approach in designing more effective biomarker-guided CHF therapy. Finally, future research should focus on better standardization of the assays, and combining the results with genetic analyses may further help to successfully translate these biomarkers into clinical practice.
Study limitations
First, this cohort consisted mainly of patients with HF with reduced ejection fraction. The low number of patients with HF with preserved ejection fraction (HF-pEF) can most likely be attributed to the fact that in The Netherlands, most patients with HF-pEF are followed in secondary referral centers or by their primary care provider, whereas our study was performed in two tertiary referral centers. Potential selection bias is not a likely reason for the low rate of patients with HF-pEF, because all consecutive patients were screened in both participating centers. Second, although we had trimonthly blood samples available for all patients, because of efficiency reasons, only two sampling moments were selected for event-free patients and three sampling moments for patients with a primary end point. In previous investigations within this cohort, we have used all available sampling moments to determine NT-proBNP, c-TnT, C-reactive protein, and glomerular and tubular renal biomarkers (16) . Those investigations demonstrated that most of these biomarkers show an increase shortly prior to the incident adverse event. Thus, we believe that by selecting baseline samples, as well as the last two samples prior to the incident end point, we retain the most informative measurements while enhancing efficiency.
Conclusion
The temporal patterns of IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4 strongly predict adverse clinical outcomes during outpatient follow-up of patients with CHF. These biomarkers, therefore, may be relevant for clinical practice as they could help detect more aggressive forms of CHF and assess patient prognosis, as well as ultimately aid in designing more effective biomarkerguided therapy.
